Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib neoadjuvant and adjuvant therapy with percutaneous ablation for poor-prognosis BCLC A hepatocellular carcinoma
2020-005504-18Phase 2Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of lenvatinib in hepatocellular carcinoma (HCC), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Local recurrence-free survival at 1 year. Started Mar 2021; status: active.
02
Drugs
lenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2020-005504-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005504-18.